Table 4.

Patients who received third EGFR-TKI

Case	Initial TKI	Re-administered TKI		Third TKI
		TKI	ILD	TKI	Therapeutic line	Concurrent prednisolone (mg)	PS	ILD	ILD onset, days from TKI start	ILD grade	ILD radiological pattern	Corticosteroid for ILD	Response	PFS (days)
1	Osi	Osi	No	Dac	6	5	1	No					NE	12
2	Osi	Gef	No	Dac	4	0	1	No					PD	112
3	Erl	Gef	Yes	Afa	5	0	2	Yes	62	3	AEP	No	NE	99
4	Osi	Afa	No	Osi	4	0	1	No					SD	125
5	Erl	Gef	No	Osi	3	0	0	Yes	201	2	AEP	Yes	PR	319
6	Osi	Dac	No	Erl*	6	0	1	No					SD	274
7	Osi	Afa	No	Dac	9	10	1	No					NE	134
8	Osi	Erl	No	Osi	3	0	1	Yes	80	3	DAD	Yes	SD	185
9	Osi	Afa	No	Osi	5	0	0	No					SD	215a
10	Osi	Afa	No	Erl	4	0	1	No					SD	298
11	Afa	Erl	No	Osi	5	0	1	Yes	285	2	HP	Yes	PR	421a
12	Afa	Osi	Yes	Osi	5	0	1	No					SD	84

AEP acute eosinophilic pneumonia, Afa afatinib, Dac dacomitinib, DAD diffuse alveolar damage, Erl erlotinib, Gef: gefitinib, HP hypersensitivity pneumonia, ILD interstitial lung disease, NE not evaluated, Osi osimertinib, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, TKI tyrosine kinase inhibitor

*With ramucirumab

^aNon-PD at the evaluated day